PTPRC and melanoma: We then tested the small MCSP+MT− cells from both patients with melanoma (n = 715 cells) and patients without melanoma (n = 61 cells) for the leukocyte marker CD45 and found that 50% (360/715) and 53% (32/61), respectively, expressed CD45 (Extended Data Fig. 1f).